The study focuses on patients unlikely to benefit from azacitidine/venetoclax or showing early resistance. ・SLS009 showed strong Phase 2 results in relapsed/refractory AML, surpassing 20% overall ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved revumenib for patients aged 1 year and older with relapsed or refractory acute myeloid leukemia ...

Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -- SELLAS’ Predictive ...

HOUSTON -- Complete response (CR) rates in relapsed/refractory NPM1-mutated acute myeloid leukemia (AML) doubled historical rates in a preliminary study of an investigational menin inhibitor. A pooled ...

– Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) – – 47% (30/64) ORR in a heavily pre-treated population, including 75% with prior ...

“ Relapsed/refractory acute myeloid leukemia is one of the most dire cancer diagnoses, with 50% of patients non-responsive to or relapsing after initial treatment and a median survival time of less ...

Three clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated significant positive results from novel triplet therapies in the treatment of relapsed or ...

“We’re truly encouraged by the consistent safety profile and the depth of responses observed with ziftomenib in combination with venetoclax and azacitidine across both newly diagnosed and ...

Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity. In a study of ...